Criteria for the operational classification of patients with eosinophilia
Persistent eosinophilia (at least 1.5 × 109/L) for at least 6 months associated with evidence of end-organ disease |
| Nonidiopathic |
| Clonal eosinophilia |
| Identification of a cytogenetic or molecular abnormality* |
| Bone marrow morphologic evidence of a myeloid disorder† |
| Reactive eosinophilia |
| Parasites, atopy, drug reaction, connective tissue disease, nonmyeloid malignancy (eg, Hodgkin lymphoma, etc) |
| Idiopathic |
| Hypereosinophilic syndrome |
Persistent eosinophilia (at least 1.5 × 109/L) for at least 6 months associated with evidence of end-organ disease |
| Nonidiopathic |
| Clonal eosinophilia |
| Identification of a cytogenetic or molecular abnormality* |
| Bone marrow morphologic evidence of a myeloid disorder† |
| Reactive eosinophilia |
| Parasites, atopy, drug reaction, connective tissue disease, nonmyeloid malignancy (eg, Hodgkin lymphoma, etc) |
| Idiopathic |
| Hypereosinophilic syndrome |
Eg, acute myeloid leukemia (AML) with t(16;16), 8p11 myeloproliferative syndromes (EMS), FIPIL1-PDGFRA fusion, etc. No distinction is made as to whether or not the cytogenetic or molecular abnormality conclusively establishes the eosinophils to be derived from the neoplastic clone.
Based on French-American-British (FAB)/WHO criteria; includes eosinophilia associated-myelodysplastic syndrome, -systemic mast cell disease, etc.